Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma

doi:10.1016/S0046-8177(98)90227-1

Human Pathology

Volume 29, Issue 2, February 1998, Pages 166-169

https://doi.org/10.1016/S0046-8177(98)90227-1 Get rights and content

Abstract

MOC-31 is a monoclonal antibody that has recently become commercially available that recognizes an epithelial-associated, transmembrane glycoprotein often expressed in epithelial tumors. Although some authors have indicated that MOC-31 immunostaining can assist in distinguishing epithelial mesotheliomas from metastatic adenocarcinomas to the pleura, others have concluded that this marker has no value in separating these conditions. To determine whether MOC-31 immunostaining can assist in discriminating epithelial pleural mesothelioma from lung adenocarcinoma or from other carcinomas metastatic to the pleura, 38 epithelial pleural mesotheliomas, 40 pulmonary adenocarcinomas, 55 nonpuhnonary adenocarcinomas, six squamous cell carcinomas of the lung (SCCLs), three small-cell lung carcinomas (SCLCs), 19 bronchial carcinoids (BCs), and 15 transitional cell carcinomas (TCCs) were studied. Reactivity was obtained in two (5%) of the mesotheliomas, in all 40 (100%) pulmonary adenocarcinomas, in 45 (82%) nonpulmonary adenocarcinomas, in six (100%) SCCLs, three (100%) SCLCs, 15 (83%) BCs, and 10 (67%) TCCs. The staining in the two positive mesotheliomas was restricted to a few cells, in contrast to the pulmonary adenocarcinomas and most of the other carcinomas where it was often strong and diffuse. It is concluded that MOC-31 can be useful in separating epithelial pleural mesothelioma from pulmonary adenocarcinoma or from other epithelial malignancies involving the pleura.

References (15)

RW Brown et al.
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma
Hum Pathol
(1993)
L De Leij et al.
Immunoperoxidase staining on frozen tissue sections as a first screening assay in the preparation of monoclonal antibodies directed against small cell carcinoma of the lung
Eur J Cancer Clin Oncol
(1984)
RL Souhami et al.
PCL Beverley et al.
Results of the central data analysis
Lung Cancer
(1988)
NG Ordóñez
The immunohistochemical diagnosis of mesothelioma
Am J Surg Pathol
(1989)
AS-Y Leong et al.
The immunohistochemistry of malignant mesothelioma
Pathol Annu
(1994)
NG Ordóñez et al.
The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma
Adv Anat Pathol
(1996)

There are more references available in the full text version of this article.

Cited by (83)

Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma
2017, Gastroenterology Clinics of North America
Citation Excerpt :
It should be noted that markers commonly associated with adenocarcinoma, such as CK7, CK19, and MOC-31, are positive in 10% to 20% of HCCs.9,24–27 In addition to being positive in approximately 90% of metastatic adenocarcinomas, these markers also can be positive in NETs and RCCs.9,26–29 This expression pattern supports the diagnosis of HCC in most cases (see Table 1).
Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens
2017, Human Pathology
Citation Excerpt :
Similarly, up to 15% of HCCs can aberrantly express CK20, which can represent a potential diagnostic pitfall in a liver biopsy, particularly when imaging studies are not typical of HCC [39,40]. This antibody recognizes epithelial cell adhesion molecule (EpCAM) and shows diffuse membranous staining in more than 90% of cholangiocarcinomas and metastatic adenocarcinomas (including gastric, pancreatic, colorectal, lung, breast, and ovarian primaries), as well as majority of urothelial carcinomas, NETs, and RCCs [5,41-44]. Although the majority of HCCs are negative, MOC-31 positivity has been observed in 10% to 20% of HCCs [5,41,42].
Well-differentiated hepatocellular carcinoma (HCC) shares overlapping histological features with benign hepatocellular lesions, including hepatocellular adenoma and focal nodular hyperplasia in non-cirrhotic liver, and with high-grade dysplastic nodule in cirrhotic liver. Several metastatic tumors, such as neuroendocrine tumor, renal cell carcinoma, adrenocortical carcinoma, melanoma, and epithelioid angiomyolipoma, can be indistinguishable from HCC on histologic grounds. Since this distinction has important therapeutic implications, judicious use of immunohistochemical markers plays an important role in establishing an accurate diagnosis, especially when limited material of tumor is available on cell block or a small core biopsy. This review describes commonly used immunohistochemical markers used in the diagnosis of HCC, highlighting advantages and disadvantages of each marker, and suggests appropriate immunohistochemical panels for specific clinicopathologic situations.
Differential expression of epithelial cell adhesion molecule in salivary gland neoplasms
2016, Annals of Diagnostic Pathology
Epithelial cell adhesion molecule (EpCAM) is the epithelial-specific molecule expressed on various epithelial cell types. The function of EpCAM involves cellular adhesion, proliferation, and signaling in both normal tissues and cancers. The purposes of this study were to investigate the EpCAM expression in salivary gland neoplasms and examine its relationship with pathologic characteristics. Forty-two cases of salivary gland neoplasms, including 20 mucoepidermoid carcinomas (MECs), 11 adenoid cystic carcinomas (ACCs), 9 pleomorphic adenomas (PAs), and 2 polymorphous low-grade adenocarcinomas (PLGAs) were enrolled. Epithelial cell adhesion molecule expression was analyzed immunohistochemically using MOC-31 and BerEP4 antibodies. Results showed that the majority of MECs and all PLGAs showed EpCAM expression in more than 50% of neoplastic cells, whereas most PAs and ACCs did not express this protein. In MECs, most EpCAM-positive neoplastic cells were clear cells, glandular epithelial cells, and intermediate cells, whereas squamous cells and mucous cells were largely negative. The expression was limited to ductal epithelium in EpCAM-positive PAs and ACCs. The decreased EpCAM expression in MECs was significantly associated with microscopically diminished cystic components, the presence of small nest invasion at invasive front, cellular anaplasia, vascular invasion, and high pathologic grade. These data suggested that EpCAM showed different expression pattern among salivary gland neoplasms and in different grades of MECs.
Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: A comparative study
2014, Human Pathology
Epithelioid mesotheliomas and breast carcinomas can present a variety of morphologic patterns. Because of this, breast carcinomas that metastasize to the pleura and lung may be confused with mesotheliomas. The aim of the present study is to compare the immunohistochemical markers currently available for the diagnosis of these 2 malignancies and to determine the best panel of markers that can be used to assist in discriminating between them. Sixty epithelioid mesotheliomas and 80 breast carcinomas (40 triple negative and 40 estrogen receptor positive) were investigated for expression of the positive mesothelioma markers calretinin, keratin 5/6, mesothelin, podoplanin, thrombomodulin, and WT1; the positive carcinoma marker claudin 4; and the breast-associated markers gross cystic disease fluid protein 15 (GCDFP-15), mammaglobin, and GATA3. All of the epithelioid mesotheliomas reacted for calretinin and keratin 5/6, 93% for WT1; 88% for podoplanin; 77% for thrombomodulin; 23% for GATA3; and 0% for claudin 4, GCDFP-15, and mammaglobin, respectively. Of the triple-negative breast carcinomas, 100% expressed claudin 4; 5%, keratin 5/6; 30%, GATA3; 18%, mammaglobin; 15%, GCDFP-15; 56%, mesothelin; 38%, calretinin; 18%, thrombomodulin; 5%, WT1; and 3%, podoplanin. Among the estrogen receptor–positive breast carcinomas, 100% were claudin 4 and GATA3 positive; 70% expressed GCDFP-15; 63%, mammaglobin; 13%, calretinin; 13%, thrombomodulin; 8%, WT1; 5%, keratin 5/6; 3%, mesothelin; and 0%, podoplanin. It is concluded that podoplanin and WT1 are the best positive mesothelioma markers for differentiating epithelioid mesotheliomas from breast carcinomas. An accurate differential diagnosis can be reached with the use of these two markers in combination with the breast-associated markers GCDFP-15, mammaglobin, and GATA3.
Broad-spectrum immunohistochemical epithelial markers: A review
2013, Human Pathology
A relatively large number of broad-spectrum immunohistochemical epithelial markers that can be used as part of the screening panels employed in the recognition of the main cell lineages during the initial evaluation of a poorly differentiated tumor are currently available. Variations exist in the sensitivity and specificity of the individual markers that have traditionally been used for the demonstration of epithelial differentiation and in the pitfalls associated with these markers. This article reviews not only the reactivity of the various pan-keratin antibodies that are often used to assist in the demonstration of epithelial differentiation, but also that of those that have recently become available. A review of the non-keratin, broad-spectrum epithelial markers that have been recognized as being useful is also presented.
Diagnostic Approach to Hepatic Mass Lesions and Role of Immunohistochemistry
2013, Surgical Pathology Clinics
Citation Excerpt :
In FNH, GS has a typical, maplike pattern.35,42 MOC31 (EPCAM) is an antibody against a cell surface glycoprotein and was initially used to separate mesothelioma from metastatic adenocarcinoma.28,74 In liver biopsies, it consistently shows membranous staining in most metastatic adenocarcinomas and CCs, although staining in HCC is negative or weakly, patchy positive.28,75,76
This review provides an overview of various hepatic mass lesions and a practical diagnostic approach, including most recent immunohistochemical stains used in clinical practice. A wide variety of benign and malignant lesions present as hepatic masses, and the differential diagnosis varies. In cirrhotic liver, the commonest malignant tumor is hepatocellular carcinoma (HCC), which needs to be differentiated from macroregenerative nodules, dysplastic nodules, and other tumors. The differential diagnosis of lesions in noncirrhotic liver in younger patients includes hepatic adenoma (HA), focal nodular hyperplasia (FNH), HCC, and other primary hepatic neoplasms and metastases. In older populations, metastases remain the most common mass lesions.

View all citing articles on Scopus

View full text

Original contributionValue of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma

Abstract

Hum Pathol

Eur J Cancer Clin Oncol

Lung Cancer

The immunohistochemical diagnosis of mesothelioma

Am J Surg Pathol

The immunohistochemistry of malignant mesothelioma

Pathol Annu

The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma

Adv Anat Pathol

Original contribution
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma